It is simple, the cure is the goal, we don’t just cover symptoms.
At GrittGene Therapeutics, our Mission is to cure patients with Myotonic Dystrophy Type 2. We develop the cure of tomorrow by combining all the tools available today. With our disease-centric approach, with the cure being the main driving force, GrittGene’s interdisciplinary platform is free from the constraints of big pharma. In our hands, alleviation of disease symptoms is just an observable effect of the cure. The collaborative environment at GrittGene combines the power of expert scientists from various branches of pharmaceutical industries and more. We employ cutting-edge technologies including CRISPR and Artificial Intelligence for tissue-specific delivery and gene-specific editing, a combination of small-molecule treatment with biologicals and gene therapy. We are not limited by internal technology; we are free to develop treatment the right way through collaboration and a combination of the complete pool of technologies and wealth of knowledge at our disposal today.
With our capacity to use a wide range of expertise and experiences in diverse aspects of drug discovery and beyond, w e believe that the effective use of all possible tools will lead us to success.
-
所属行业
-
生物技术研究
-
规模
-
2-10 人
-
总部
-
Glendale，California
-
类型
-
私人持股
-
创立
-
2022
